• category:Pipeline
Enrollment opens for Clearside Biomedical's ODYSSEY phase 2b trial for wet AMD
Pipeline

Enrollment opens for Clearside Biomedical's ODYSSEY phase 2b trial for wet AMD

CLS-AX is being assessed for suprachoroidal delivery using the company’s proprietary CSC Microinjector.
Target enrollment achieved in trial for RP associated with Usher syndrome
Pipeline

Target enrollment achieved in trial for RP associated with Usher syndrome

The phase 1/2 study is assessing NPI-001, developed to block oxidative stress associated with RP and other blinding eye diseases.
Positive 12-month data reported in Coave's ongoing RP phase 1/2 trial
Pipeline

Positive 12-month data reported in Coave's ongoing RP phase 1/2 trial

Gene therapy candidate targets treatment for a rare form of retinitis pigmentosa: PDE6B RP.
4DMT reports positive interim data from phase 1/2 wet AMD trial
Pipeline

4DMT reports positive interim data from phase 1/2 wet AMD trial

4D Molecular Therapeutics’ intravitreal study on novel genetic medicine indicates well-tolerance for all doses.
Annexon releases topline data for phase 2 GA study
Pipeline

Annexon releases topline data for phase 2 GA study

ARCHER trial is assessing ANX007 as the first complement therapy for preserving visual acuity. 
Alimera completes patient enrollment for DME study on ILUVIEN
Pipeline

Alimera completes patient enrollment for DME study on ILUVIEN

NEW DAY study is evaluating the intravitreal implant as a baseline therapy compared to aflibercept.
Tanfanercept fails DED phase 3 trial primary endpoints
Pipeline

Tanfanercept fails DED phase 3 trial primary endpoints

HanAll Biopharma reports highly statistically significant improvement in secondary measures of VELOS-3 study.
Positive topline data reported in phase 3 DME trial of OCS-01
Pipeline

Positive topline data reported in phase 3 DME trial of OCS-01

Oculis’s stage 1 of the DIAMOND study supports potential for OCS-01 to become the first topical eye drop and noninvasive DME treatment.
RegenxBio to globally expand pivotal trials for wet AMD gene therapy
Pipeline

RegenxBio to globally expand pivotal trials for wet AMD gene therapy

Company shares updates on development and commercialization plans for ABBV-RGX-314.
Enrollment concludes for Invirsa's first-in-human DED study
Pipeline

Enrollment concludes for Invirsa's first-in-human DED study

Lead compound INV-102 is formulated to promote ocular DNA repair.
First patient dosed in phase 2, China-based TED trial
Pipeline

First patient dosed in phase 2, China-based TED trial

The RESTORE trial is assessing the proptosis responder rate following dosage of IBI311, an IGF-1R monoclonal antibody.
Formosa and AimMax submit joint NDA for ocular pain and inflammation
Pipeline

Formosa and AimMax submit joint NDA for ocular pain and inflammation

Novel ophthalmic APP13007 is designed to provide eye comfort and enhanced drug penetration into ocular tissues.
Phase 2 data of TTHX1114 shows promise for improving post-DSO visual recovery rate
Pipeline

Phase 2 data of TTHX1114 shows promise for improving post-DSO visual recovery rate

Trefoil Therapeutics’ first investigational FGF-1 improved BCVA and CCT.
FDA accepts sBLA for Vabysmo to treat RVO
Pipeline

FDA accepts sBLA for Vabysmo to treat RVO

If approved, Vabysmo would become the first bispecific antibody available for blinding retinal conditions.
Atia Vision presents first-in-human clinical data from novel IOL
Pipeline

Atia Vision presents first-in-human clinical data from novel IOL

Early results show potential for both cataract and presbyopia correction.
Visus releases topline data from phase 3 trial of Brimochol PF
Pipeline

Visus releases topline data from phase 3 trial of Brimochol PF

BRIO-I trial successfully meets prespecified FDA primary endpoints.
Endogena concludes enrollment ahead of schedule for RP trial
Pipeline

Endogena concludes enrollment ahead of schedule for RP trial

Phase 1/2a dose expansion trial is assessing the safety and tolerability of EA-2353.
Nanoscope releases key efficacy data from phase 2b trial for RP
Pipeline

Nanoscope releases key efficacy data from phase 2b trial for RP

Clinically significant vision improvement observed among patients treated with the optogenetic therapy MCO-010.
Favorable preliminary data reported for KIO-301 in RP treatment
Pipeline

Favorable preliminary data reported for KIO-301 in RP treatment

Kiora Pharmaceuticals' first-in-human ABACUS study suggests promising vision function restoration.
BVI completes enrollment for IDE study on hydrophobic trifocal IOL
Pipeline

BVI completes enrollment for IDE study on hydrophobic trifocal IOL

FINEVISION HP builds on the company’s first and original patented diffractive trifocal optic.